For men with high-risk pathology at radical prostatectomy, exposure to results of a genomic test that classifies 5-year risk of metastasis reduces decisional conflict, according to findings of a prospective study presented at the American Society of Clinical Oncology annual meeting in Chicago.
An ongoing phase II trial investigating abiraterone acetate (ZYTIGA) and enzalutamide (XTANDI) as treatment for men with chemotherapy-naïve metastatic castrate-resistant prostate cancer is aiming to characterize the effects of these targeted hormonal therapies on cognition and mood.
Multiparametric magnetic resonance imaging (mpMRI) identifies a significant percentage of men who present with an elevated serum PSA level who may safely avoid prostate biopsy, British researchers report.
“It appears that baseline PSA is a lot more predictive than either family history or race alone and should be used to risk stratify screening,” the co-lead author of a recent study tells Urology Times.
Concordance with National Cancer Comprehensive Network recommendations about follow-up during active surveillance for low-risk prostate cancer is generally low across urology practices in Michigan, reported researchers from the Michigan Urological Surgery Improvement Collaborative at the AUA annual meeting in San Diego.
A Veterans Administration Cooperative Study investigating chemotherapy after prostatectomy for high-risk prostate cancer was underpowered to show a statistically significant benefit of early adjuvant chemotherapy versus observation as the standard of care in the primary endpoint analysis of progression-free survival.
Fusion biopsy, salvage versus adjuvant radiation therapy, and superextended versus extended pelvic lymph node dissection are also covered in the take home messages on prostate cancer from the 2016 AUA annual meeting.